Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13680960 | 0.87 | CCNE2 (0.38) | FAAHMTNR1BCCNE2CDK4CCND1 | |
| SCHEMBL24258780 | 0.75 | FAAH (0.39) | FAAHMTNR1BCCNE2CDK4CCND1 | |
| SCHEMBL13361951 | 0.72 | HDAC1 (0.61) | FAAHHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24259040 | 0.71 | MAPT (0.40) | FAAHMTNR1BTSHRTRPV1MTNR1A | |
| SCHEMBL12128445 | 0.71 | — | — | |
| SCHEMBL22352802 | 0.71 | HDAC1 (0.45) | FAAHMTNR1BCCNE2CDK4CCND1 | |
| SCHEMBL7363589 | 0.70 | HDAC1 (0.65) | FAAHTSHRHDAC3HDAC4HDAC1 | |
| SCHEMBL3194484 | 0.70 | FAAH (0.46) | FAAH | |
| SCHEMBL21894059 | 0.70 | — | — | |
| SCHEMBL13478083 | 0.69 | FAAH (0.48) | FAAHHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | FAAH 2934/4885MTNR1B 679/4885CCNE2 4231/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | FAAH 2934/4885MTNR1B 679/4885CCNE2 4231/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | FAAH 2505/4885MTNR1B 560/4885CCNE2 2714/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | FAAH 2934/4885MTNR1B 679/4885CCNE2 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.